Borosil Scientific Ltd

Borosil Scientific Ltd has announced that its 35th Annual General Meeting (AGM) will be held on Friday, September 25, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) or Other Audio-Visual Means (OAVM), in compliance with relevant regulations. The Annual Report for FY 2025-26, including the AGM notice, will be sent electronically to eligible members by August 21, 2026. Remote e-voting will be open from September 22 to September 24, 2026. Members registered as of September 18, 2026, are eligible to vote and attend.

Borosil Scientific Ltd's Board of Directors met on August 3, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026 (Standalone & Consolidated). The board also approved modifications to the company's ESOP schemes, SP-ESOP 2023 and BSL ESOS. These amendments aim to facilitate share arrangements for option holders through primary issuance or trust route acquisitions and increase the discount limit for new options from 10% to 20% of the market price. The limited review reports from the statutory auditor were also attached.

Borosil Scientific's consolidated PAT came in at ₹4.36 Cr for Q1 FY27, versus a ₹4.21 Cr loss a year ago, on revenue of ₹106.75 Cr (+11.2% YoY). No street estimates or analyst previews for this stock turned up in a web search, so the print can't be graded against consensus — flagged as unknown rather than guessed. There is no formal management guidance on record either from our database or from public sources, so the result is being read purely against its own trend line. Sequentially, revenue fell 25.4% from Q4 FY26's ₹143.17 Cr and PAT dropped 84% from ₹27.25 Cr — Q4 is typically the seasonally heavier quarter for institutional/lab-equipment billing at this company, so the QoQ decline reads as normalization rather than a fresh deterioration. The YoY turnaround needs an asterisk: the Q1 FY26 base included a one-off ₹6.61 Cr VRS exceptional charge at the Nashik plant that pushed that quarter into a loss. Stripping it out, adjusted Q1 FY26 PAT was ~₹2.40 Cr, making underlying YoY PAT growth closer to +81% rather than a straightforward loss-to-profit swing — still a real improvement, just not as dramatic as the headline turnaround implies. On margins, NPM expanded YoY to 3.98% from -4.26% and OPM to 7.92% from -1.81%, but both compressed sharply from Q4 FY26's 18.76%/22.43% — driven mainly by employee benefits expense rising 22.5% QoQ to ₹21.98 Cr even as revenue fell, since headcount-linked costs didn't scale down with the smaller order book. At the segment level, Glassware swung to a positive ₹0.19 Cr PBT versus a ₹2.40 Cr loss a year ago and a ₹1.73 Cr loss last quarter — a genuine, if small, turnaround. Standalone PAT of ₹6.84 Cr is 57% higher than the ₹4.36 Cr consolidated figure because subsidiary Goel Scientific Glass Works lost ₹2.36 Cr on ₹7.63 Cr of revenue this quarter, a divergence worth flagging since standalone-only readers will see a materially better number. The quarter also sits alongside two governance items disclosed with the results: Sharad Tiwari's exit from a senior managerial role (July 14) and the board's same-day approval of ESOP scheme amendments raising the maximum option-grant discount from 10% to 20% — neither tied directly to the P&L but both worth tracking into next quarter. No management press release accompanied this filing, so there's no company framing to reconcile against the numbers.

Borosil Scientific Ltd has announced that its Board of Directors will convene on August 3, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results, both standalone and consolidated, for the first quarter ended June 30, 2026. In line with SEBI regulations, the company has also informed that the trading window for its equity shares will remain closed for designated persons and their immediate relatives until 48 hours after the declaration of these financial results. The trading window was initially closed from July 01, 2026. This announcement is also available on the company's official website.

Borosil Scientific Ltd announced that Mr. Sharad Tiwari, Head - Sales (Domestic and International) – Pharmaceutical Primary Packaging, has ceased to be a Senior Managerial Personnel of the Company effective July 14, 2026. This change is attributed to an internal reporting structure adjustment. Importantly, Mr. Tiwari continues his association with the company, indicating a potential shift in role rather than a departure. The company has requested this information be taken on record.

Borosil Scientific Ltd has responded to an email from the BSE dated June 30, 2026, regarding a recent increase in the stock's price and volume. The company stated that it has not withheld any material information or events that require disclosure under SEBI regulations. Borosil Scientific clarified that the observed market behavior is purely driven by market forces and not due to any undisclosed material information. The company has requested the BSE to take this clarification on record.

Borosil Scientific Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 01, 2026, until 48 hours after the declaration of the Un-audited Financial Results (Standalone & Consolidated) for the quarter ending June 30, 2026. The specific date for the Board Meeting to approve these results will be communicated separately.

Borosil Scientific Ltd's Nomination and Remuneration Committee approved the grant of 18,700 stock options under its Employee Stock Option Scheme on May 20, 2026. Each option allows the holder to apply for one equity share of Re.1 each. The options were granted at ₹108 per option, a ~10% discount on the market price. The options vest over four years, with 25% vesting annually. The exercise period is 5 years from the vesting date.

Borosil Scientific Ltd has re-appointed Mr. Vinayak Madhukar Patankar as Whole-time Director & CEO for a period of 3 years effective from December 2, 2026, subject to shareholder approval. The board also approved audited financial statements and results for the year ended March 31, 2026, and authorized seeking shareholder approval to raise up to ₹250 crores. Mr. Sanjay Gupta resigned as Company Secretary and Compliance Officer, and Mr. Ramavtar Sharma was appointed in his place, effective May 21, 2026.

The Board of Directors of Borosil Scientific Ltd approved the audited financial statements and results (standalone & consolidated) for the year ended March 31, 2026. They authorized seeking shareholder approval to raise up to ₹250 crores through various methods. Mr. Vinayak Madhukar Patankar was re-appointed as Whole-time Director & CEO for 3 years. Mr. Sanjay Gupta resigned as Company Secretary and Compliance Officer, and Mr. Ramavtar Sharma was appointed in his place, effective May 21, 2026.